MannKind Corporation (NASDAQ: MNKD)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
MannKind Corporation Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
MannKind Corporation Company Info
MannKind Corporation
News & Analysis
The company is coming off an FDA approval for its second marketed drug.
Investors are hyperventilating after a delay for its inhaled medicine.
An analyst is excited about the company's prospects.
MannKind's reverse stock split gave investors the blues.
The biopharma's reverse split isn't a hit with investors.
Biotech stocks are known for their high growth, but they can also be toxic for your portfolio if you don't invest wisely.
A handful of positive developments caused shares to rally.
What does MannKind's update this week mean for investors?
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
MNKD earnings call for the period ending June 30, 2022.
MNKD earnings call for the period ending March 31, 2022.
MNKD earnings call for the period ending December 31, 2021.
MNKD earnings call for the period ending June 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.